These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Periplasmic expression optimization of VEGFR2 D3 adopting response surface methodology: antiangiogenic activity study. Cao W; Li H; Zhang J; Li D; Acheampong DO; Chen Z; Wang M Protein Expr Purif; 2013 Aug; 90(2):55-66. PubMed ID: 23680780 [TBL] [Abstract][Full Text] [Related]
7. An active murine-human chimeric Fab antibody derived from Escherichia coli, potential therapy against over-expressing VEGFR2 solid tumors. Huang J; Liang J; Tang Q; Wang Z; Chen L; Zhu J; Feng Z Appl Microbiol Biotechnol; 2011 Sep; 91(5):1341-51. PubMed ID: 21604194 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of Endothelial SCUBE2 (Signal Peptide-CUB-EGF Domain-Containing Protein 2), a Novel VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) Coreceptor, Suppresses Tumor Angiogenesis. Lin YC; Liu CY; Kannagi R; Yang RB Arterioscler Thromb Vasc Biol; 2018 May; 38(5):1202-1215. PubMed ID: 29545238 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of novel antimouse VEGFR2 antibodies as potential antiangiogenic or vascular targeting agents for tumor therapy. Ran S; Huang X; Downes A; Thorpe PE Neoplasia; 2003; 5(4):297-307. PubMed ID: 14511401 [TBL] [Abstract][Full Text] [Related]
10. Generation and characterization of a human nanobody against VEGFR-2. Ma L; Gu K; Zhang CH; Chen XT; Jiang Y; Melcher K; Zhang J; Wang M; Xu HE Acta Pharmacol Sin; 2016 Jun; 37(6):857-64. PubMed ID: 27108602 [TBL] [Abstract][Full Text] [Related]
13. Direct contacts between extracellular membrane-proximal domains are required for VEGF receptor activation and cell signaling. Yang Y; Xie P; Opatowsky Y; Schlessinger J Proc Natl Acad Sci U S A; 2010 Feb; 107(5):1906-11. PubMed ID: 20080685 [TBL] [Abstract][Full Text] [Related]
14. Suppression of angiogenesis and tumor growth by recombinant T4 phages displaying extracellular domain of vascular endothelial growth factor receptor 2. Zuo S; Dai G; Wang L; Wen Y; Huang Z; Yang W; Ma W; Ren X Arch Virol; 2019 Jan; 164(1):69-82. PubMed ID: 30259141 [TBL] [Abstract][Full Text] [Related]
15. The impact of the receptor binding profiles of the vascular endothelial growth factors on their angiogenic features. Nieminen T; Toivanen PI; Rintanen N; Heikura T; Jauhiainen S; Airenne KJ; Alitalo K; Marjomäki V; Ylä-Herttuala S Biochim Biophys Acta; 2014 Jan; 1840(1):454-63. PubMed ID: 24112971 [TBL] [Abstract][Full Text] [Related]
16. Generation of recombinant extracellular fragment of vascular endothelial growth factor receptor 2 and specific monoclonal antibodies to this receptor. Korchagina AA; Shein SA; Leopol'd AV; Volgina NE; Gurina OI; Lazarenko IP; Antonova OM; Baklaushev VP; Chekhonin VP Bull Exp Biol Med; 2014 Jan; 156(3):357-62. PubMed ID: 24771375 [TBL] [Abstract][Full Text] [Related]
17. The structural basis for the function of two anti-VEGF receptor 2 antibodies. Franklin MC; Navarro EC; Wang Y; Patel S; Singh P; Zhang Y; Persaud K; Bari A; Griffith H; Shen L; Balderes P; Kussie P Structure; 2011 Aug; 19(8):1097-107. PubMed ID: 21827946 [TBL] [Abstract][Full Text] [Related]
18. Simultaneous targeting of VEGF-receptors 2 and 3 with immunoliposomes enhances therapeutic efficacy. Orleth A; Mamot C; Rochlitz C; Ritschard R; Alitalo K; Christofori G; Wicki A J Drug Target; 2016; 24(1):80-9. PubMed ID: 26204325 [TBL] [Abstract][Full Text] [Related]
19. Cooperative interactions between VEGFR2 extracellular Ig-like subdomains ensure VEGFR2 dimerization. King C; Wirth D; Workman S; Hristova K Biochim Biophys Acta Gen Subj; 2017 Nov; 1861(11 Pt A):2559-2567. PubMed ID: 28847506 [TBL] [Abstract][Full Text] [Related]
20. VEGFR1(D2) in drug discovery: Expression and molecular characterization. Di Stasi R; Diana D; Capasso D; Palumbo R; Romanelli A; Pedone C; Fattorusso R; D'Andrea LD Biopolymers; 2010; 94(6):800-9. PubMed ID: 20564033 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]